OrganoClick AB (publ) Logo

OrganoClick AB (publ)

ORGC.ST

(0.8)
Stock Price

2,75 SEK

-14.28% ROA

-37.79% ROE

-17.11x PER

Market Cap.

292.391.640,00 SEK

119.98% DER

0% Yield

-12.34% NPM

OrganoClick AB (publ) Stock Analysis

OrganoClick AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

OrganoClick AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

2 DER

The stock maintains a fair debt to equity ratio (80%), indicating a reasonable balance between the money it owes and the ownership it possesses.

3 ROE

Negative ROE (-51.81%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-25.39%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (5.96x) suggests it's overvalued, potentially making it an expensive investment.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-13), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

OrganoClick AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

OrganoClick AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

OrganoClick AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

OrganoClick AB (publ) Revenue
Year Revenue Growth
2012 1.077.159
2013 7.752.140 86.11%
2014 20.894.000 62.9%
2015 30.462.000 31.41%
2016 38.847.000 21.58%
2017 74.682.000 47.98%
2018 78.395.000 4.74%
2019 85.480.000 8.29%
2020 96.457.000 11.38%
2021 110.063.000 12.36%
2022 115.048.000 4.33%
2023 133.796.000 14.01%
2023 145.871.000 8.28%
2024 154.984.000 5.88%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

OrganoClick AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2012 0
2013 2.147.367 100%
2014 5.954.000 63.93%
2015 3.684.000 -61.62%
2016 3.321.000 -10.93%
2017 3.469.000 4.27%
2018 3.374.000 -2.82%
2019 4.295.000 21.44%
2020 5.451.000 21.21%
2021 7.503.000 27.35%
2022 12.202.000 38.51%
2023 7.552.000 -61.57%
2023 1.229.000 -514.48%
2024 6.368.000 80.7%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

OrganoClick AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 4.617.639
2013 9.123.391 49.39%
2014 12.836.000 28.92%
2015 14.720.000 12.8%
2016 17.823.000 17.41%
2017 11.244.000 -58.51%
2018 11.152.000 -0.82%
2019 10.572.000 -5.49%
2020 10.651.000 0.74%
2021 11.572.000 7.96%
2022 14.020.000 17.46%
2023 12.716.000 -10.25%
2023 13.799.000 7.85%
2024 15.228.000 9.38%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

OrganoClick AB (publ) EBITDA
Year EBITDA Growth
2012 -7.866.347
2013 -11.901.955 33.91%
2014 -12.838.000 7.29%
2015 -18.692.000 31.32%
2016 -24.872.000 24.85%
2017 -17.477.000 -42.31%
2018 -11.344.000 -54.06%
2019 -3.097.000 -266.29%
2020 -4.332.000 28.51%
2021 -12.456.000 65.22%
2022 -23.627.000 47.28%
2023 4.120.000 673.47%
2023 6.592.000 37.5%
2024 14.116.000 53.3%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

OrganoClick AB (publ) Gross Profit
Year Gross Profit Growth
2012 234.997
2013 1.565.904 84.99%
2014 7.243.000 78.38%
2015 10.985.000 34.06%
2016 13.675.000 19.67%
2017 29.420.000 53.52%
2018 15.749.000 -86.81%
2019 17.763.000 11.34%
2020 20.197.000 12.05%
2021 18.509.000 -9.12%
2022 12.935.000 -43.09%
2023 31.808.000 59.33%
2023 27.968.000 -13.73%
2024 45.144.000 38.05%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

OrganoClick AB (publ) Net Profit
Year Net Profit Growth
2012 -7.985.964
2013 -10.383.565 23.09%
2014 -15.605.000 33.46%
2015 -19.960.000 21.82%
2016 -29.919.000 33.29%
2017 -27.574.000 -8.5%
2018 -20.245.000 -36.2%
2019 -18.356.000 -10.29%
2020 -19.521.000 5.97%
2021 -31.033.000 37.1%
2022 -41.621.000 25.44%
2023 -16.500.000 -152.25%
2023 -15.772.000 -4.62%
2024 -11.392.000 -38.45%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

OrganoClick AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

OrganoClick AB (publ) Free Cashflow
Year Free Cashflow Growth
2012 -19.074.153
2013 -782.541 -2337.46%
2014 -23.553.000 96.68%
2015 -35.858.000 34.32%
2016 -28.715.000 -24.88%
2017 -30.731.000 6.56%
2018 -23.753.000 -29.38%
2019 -18.020.000 -31.81%
2020 -13.927.000 -29.39%
2021 -52.337.000 73.39%
2022 -35.351.000 -48.05%
2023 -8.077.000 -337.67%
2023 -378.000 -2036.77%
2024 8.253.000 104.58%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

OrganoClick AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2012 -18.465.405
2013 313.544 5989.25%
2014 -17.279.000 101.81%
2015 -24.416.000 29.23%
2016 -15.549.000 -57.03%
2017 -20.716.000 24.94%
2018 -19.165.000 -8.09%
2019 -11.013.000 -74.02%
2020 5.471.000 301.3%
2021 -37.688.000 114.52%
2022 -21.223.000 -77.58%
2023 533.000 4081.8%
2023 1.051.000 49.29%
2024 10.973.000 90.42%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

OrganoClick AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2012 608.748
2013 1.096.085 44.46%
2014 6.274.000 82.53%
2015 11.442.000 45.17%
2016 13.166.000 13.09%
2017 10.015.000 -31.46%
2018 4.588.000 -118.29%
2019 7.007.000 34.52%
2020 19.398.000 63.88%
2021 14.649.000 -32.42%
2022 14.128.000 -3.69%
2023 8.610.000 -64.09%
2023 1.429.000 -502.52%
2024 2.720.000 47.46%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

OrganoClick AB (publ) Equity
Year Equity Growth
2012 13.287.238
2013 21.635.662 38.59%
2014 6.628.000 -226.43%
2015 59.481.000 88.86%
2016 41.477.000 -43.41%
2017 54.286.000 23.6%
2018 34.798.000 -56%
2019 102.471.000 66.04%
2020 82.944.000 -23.54%
2021 107.729.000 23.01%
2022 67.556.000 -59.47%
2023 53.407.000 -26.49%
2023 61.063.000 12.54%
2024 50.634.000 -20.6%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

OrganoClick AB (publ) Assets
Year Assets Growth
2012 20.206.568
2013 30.329.593 33.38%
2014 24.592.000 -23.33%
2015 82.313.000 70.12%
2016 83.785.000 1.76%
2017 101.778.000 17.68%
2018 88.103.000 -15.52%
2019 173.199.000 49.13%
2020 152.802.000 -13.35%
2021 188.386.000 18.89%
2022 162.856.000 -15.68%
2023 150.749.000 -8.03%
2023 162.226.000 7.07%
2024 162.239.000 0.01%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

OrganoClick AB (publ) Liabilities
Year Liabilities Growth
2012 6.919.330
2013 8.693.932 20.41%
2014 17.964.000 51.6%
2015 22.832.000 21.32%
2016 42.308.000 46.03%
2017 47.492.000 10.92%
2018 53.305.000 10.91%
2019 70.728.000 24.63%
2020 69.858.000 -1.25%
2021 80.657.000 13.39%
2022 95.300.000 15.37%
2023 97.342.000 2.1%
2023 101.163.000 3.78%
2024 111.606.000 9.36%

OrganoClick AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.41
Net Income per Share
-0.17
Price to Earning Ratio
-17.11x
Price To Sales Ratio
2.11x
POCF Ratio
35.33
PFCF Ratio
-297.75
Price to Book Ratio
7.13
EV to Sales
2.4
EV Over EBITDA
54.28
EV to Operating CashFlow
40.08
EV to FreeCashFlow
-337.26
Earnings Yield
-0.06
FreeCashFlow Yield
-0
Market Cap
0,29 Bil.
Enterprise Value
0,33 Bil.
Graham Number
1.28
Graham NetNet
-0.58

Income Statement Metrics

Net Income per Share
-0.17
Income Quality
-0.52
ROE
-0.38
Return On Assets
-0.11
Return On Capital Employed
-0.16
Net Income per EBT
1.17
EBT Per Ebit
1.53
Ebit per Revenue
-0.07
Effective Tax Rate
-0.02

Margins

Sales, General, & Administrative to Revenue
0.11
Research & Developement to Revenue
0.05
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.26
Operating Profit Margin
-0.07
Pretax Profit Margin
-0.11
Net Profit Margin
-0.12

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.08
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
1.12
Capex to Revenue
0.07
Capex to Depreciation
0.59
Return on Invested Capital
-0.11
Return on Tangible Assets
-0.14
Days Sales Outstanding
67.35
Days Payables Outstanding
55.73
Days of Inventory on Hand
138.36
Receivables Turnover
5.42
Payables Turnover
6.55
Inventory Turnover
2.64
Capex per Share
0.09

Balance Sheet

Cash per Share
0,16
Book Value per Share
0,52
Tangible Book Value per Share
0.08
Shareholders Equity per Share
0.42
Interest Debt per Share
0.56
Debt to Equity
1.2
Debt to Assets
0.3
Net Debt to EBITDA
6.36
Current Ratio
0.8
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
-0,03 Bil.
Invested Capital
55027999
Working Capital
-0,02 Bil.
Intangibles to Total Assets
0.26
Average Receivables
0,03 Bil.
Average Payables
0,01 Bil.
Average Inventory
38105500
Debt to Market Cap
0.17

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

OrganoClick AB (publ) Dividends
Year Dividends Growth

OrganoClick AB (publ) Profile

About OrganoClick AB (publ)

OrganoClick AB (publ), a material and chemical technology company, develops, produces, and markets fiber-based materials and chemicals for treatment of wood, technical textile and nonwoven, and bio composites in Sweden. It offers OrganoWood, a wood preservative technology and wood preservative that gives wood enhanced durability against rot and fire primarily for construction companies and consumers; OrganoTex, a biodegradable durable water repellent technology and textile treatment that makes textile products water repellent, as well as offers shoe and clothes care products; and OrganoComp, a biobased plastic-free and degradable bio-composite used for making 3D-shaped objects that replaces hard plastic materials. The company also provides consumer products, including a range of maintenance and cleaning products for wood, facades, roofs, and terraces, as well as for car care under the BIOkleen name; OC-BioBinder, a biobased, plastic-free, and degradable binder used by industrial customers as a replacement for plastic binders in nonwoven and technical textiles; and OC-AquaSil Tex, a biodegradable hydrophobing product used to replace PFAS in nonwovens, specialty papers, and technical textiles. The company was founded in 2006 and is headquartered in Täby, Sweden.

CEO
Mr. Marten Hellberg
Employee
40
Address
LinjalvAegen 9
Täby, 187 66

OrganoClick AB (publ) Executives & BODs

OrganoClick AB (publ) Executives & BODs
# Name Age
1 Ms. Jessica Sundborg
Executive Officer
70
2 Mr. Peter Rydja
Vice President and Head of Business Unit Green Coatings & Maintenance products
70
3 Mr. Mattias Bodin
Environmental & Sustainability Director
70
4 Mr. Mikael Wickström
Technical Director
70
5 Ms. Carin Eklund
Chief Financial Officer
70
6 Mr. Daniel Lund
Chief Operating Officer
70
7 Mr. Marten Hellberg
Co-founder & Chief Executive Officer
70

OrganoClick AB (publ) Competitors

Eolus Vind AB (publ) Logo
Eolus Vind AB (publ)

EOLU-B.ST

(3.5)
Zaptec AS Logo
Zaptec AS

ZAP.OL

(1.8)
NOTE AB (publ) Logo
NOTE AB (publ)

NOTE.ST

(2.8)
GomSpace Group AB (publ) Logo
GomSpace Group AB (publ)

GOMX.ST

(0.8)
Cadeler A/S Logo
Cadeler A/S

CADLR.OL

(2.5)